Elevation Oncology completes acquisition by Concentra Biosciences, shares delisted

Elevation Oncology, Inc.

Concentra Biosciences acquires Elevation Oncology for $0.36 per share plus contingent value right (CVR).
67.09% of shares tendered in the offer, satisfying the Minimum Tender Condition.
All directors resign at closing; Kevin Tang becomes sole director of the surviving corporation.
CEO/CFO Tammy Furlong terminated without cause, receives 12 months salary plus $600,000 lump sum.
Company requests delisting from Nasdaq and deregistration under Exchange Act.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.